Diabetic Cardiomyopathy and Its Prevention by Nrf2: Current Status

다국어 초록 (Multilingual Abstract)

Diabetic cardiomyopathy (DCM), as one of the major cardiac complications in diabetic patients, is known to related with oxidative stress that is due to a severe imbalance between reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) generation and their clearance by antioxidant defense systems. Transcription factor nuclear factor NF-E2-related factor 2 (Nrf2) plays an important role in maintaining the oxidative homeostasis by regulating multiple downstream antioxidants. Diabetes may up-regulate several antioxidants in the heart as a compensative mechanism at early stage, but at late stage, diabetes not only generates extra ROS and/or RNS but also impairs antioxidant capacity in the heart, including Nrf2. In an early study, we have established that Nrf2 protect the cardiac cells and heart from high level of glucose in vitro and hyperglycemia in vivo, and in the following study demonstrated the significant down-regulation of cardiac Nrf2 expression in diabetic animals and patients. Using Nrf2-KO mice or Nrf2 inducers, blooming evidence has indicated the important protection by Nrf2 from cardiac pathogenesis in the diabetes. Therefore, this brief review summarizes the status of studies on Nrf2’s role in preventing DCM and even other complications, the need for new and safe Nrf2 inducer screening and the precaution for the undesirable side of Nrf2 under certain conditions.

참고문헌 (Reference)

1 Miao X, "Zinc protects against diabetes-induced pathogenic changes in the aorta : roles of metallothionein and nuclear factor(erythroid-derived 2)-like 2" 12 : 54-, 2013

2 Chen Y, "Weak antioxidant defenses make the heart a target for damage in copper-deficient rats" 17 : 529-536, 1994

3 Zhong Q, "Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy" 54 : 3941-3948, 2013

4 Zheng H, "Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy" 60 : 3055-3066, 2011

5 Miao X, "Therapeutic effect of MG132 on the aortic oxidative damage and inflammatory response in OVE26 type 1 diabetic mice" 879516-, 2013

6 Wang Y, "Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB" 304 : H567-H578, 2013

7 Ding Y, "The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells" 83 : 845-854, 2013

8 Grossman R, "The dark side of Nrf2" 80 : 284-286, 2013

9 Marchan R, "The cytoprotective and the dark side of Nrf2" 87 : 2047-2050, 2013

10 Nguyen T, "The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress" 284 : 13291-13295, 2009

11 Uruno A, "The Keap1-Nrf2 system prevents onset of diabetes mellitus" 33 : 2996-3010, 2013

12 Li J, "Targeting the Nrf2 pathway against cardiovascular disease" 13 : 785-794, 2009

13 Rajasekaran NS, "Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice" 14 : 957-971, 2011

14 Cai L, "Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy" 41 : 851-861, 2006

15 Miao X, "Sulforaphane prevention of diabetes-induced aortic damage was associated with the up-regulation of Nrf2 and its downstream antioxidants" 9 : 84-, 2012

16 Wang Y, "Sulforaphane attenuation of type 2 diabetes-induced aortic damage was associated with the upregulation of Nrf2 expression and function" 2014 : 123963-, 2014

17 Willis MS, "Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease" 106 : 463-478, 2010

18 Shin S, "Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide" 620 : 138-144, 2009

19 Bashmakov YK, "Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients" 2014 : 816307-, 2014

20 Guo R, "Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-kappaB pathway" 11 : 92-102, 2014

21 Chuengsamarn S, "Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial" 25 : 144-150, 2014

22 Sadi G, "Redox regulation of antioxidant enzymes: post-translational modulation of catalase and glutathione peroxidase activity by resveratrol in diabetic rat liver" 393 : 111-122, 2014

23 Zheng X, "Protective effects of chronic resveratrol treatment on vascular inflammatory injury in steptozotocin-induced type 2 diabetic rats: role of NF-kappa B signaling" 720 : 147-157, 2013

24 Luo ZF, "Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome" 88 : 512-520, 2011

25 Cui W, "Prevention of diabetic nephropathy by sulforaphane: possible role of nrf2 upregulation and activation" 2012 : 821936-, 2012

26 Li B, "Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy" 2012 : 216512-, 2012

27 Bai Y, "Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation" 57 : 82-95, 2013

28 Cui W, "Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice" 304 : E87-E99, 2013

29 Thornalley PJ, "Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals" 827 : 36-44, 1985

30 Yang L, "Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications" 294 : E987-E992, 2008

31 Cai L, "Oxidative stress and diabetic cardiomyopathy: a brief review" 1 : 181-193, 2001

32 Yagishita Y, "Nrf2 protects pancreatic β-cells from oxidative and nitrosative stress in diabetic model mice" 63 : 605-618, 2014

33 He X, "Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes" 46 : 47-58, 2009

34 Kannan S, "Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy" 100 : 63-73, 2013

35 Zhang YK, "Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet" 264 : 305-314, 2012

36 Negi G, "Nrf2 and NF-kappaB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes" 8 : 294-304, 2011

37 Himmelfarb J, "New therapies for diabetic kidney disease" 369 : 2549-2550, 2013

38 Ceriello A, "New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy" 26 : 1589-1596, 2003

39 Xu Z, "NRF2 plays a protective role in diabetic retinopathy in mice" 57 : 204-213, 2014

40 Adeghate E, "Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review" 261 : 187-191, 2004

41 Zhou G, "Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart" 52 : 655-666, 2008

42 Cai L, "Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage" 275 : 38957-38960, 2000

43 Bruce CR, "Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism" 52 : 2338-2345, 2003

44 Cai L, "Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy" 54 : 1829-1837, 2005

45 Wang Y, "Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression" 306 : E1239-E1247, 2014

46 Liu Y, "Inhibition of JNK by compound C66 prevents pathological changes of the aorta in STZ-induced diabetes" 18 : 1203-1212, 2014

47 Wang Y, "Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling" 58 : 1391-1402, 2009

48 Filippo C, "Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion" 54 : 803-810, 2005

49 Cheng X, "Gestational diabetes mellitus impairs Nrf2-mediated adaptive antioxidant defenses and redox signaling in fetal endothelial cells in utero" 62 : 4088-4097, 2013

50 Doroshow JH, "Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin" 65 : 128-135, 1980

51 Xu J, "Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice" 61 : 3208-3218, 2012

52 Giannini C, "Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus" 23 : 539-546, 2007

53 Monkemann H, "Early molecular events in the development of the diabetic cardiomyopathy" 23 : 331-336, 2002

54 Koh KK, "Does reversal of oxidative stress and inflammation provide vascular protection?" 81 : 649-659, 2009

55 Quesada AR, "Direct reaction of H2O2 with sulfhydryl groups in HL-60 cells : zinc-metallothionein and other sites" 334 : 241-250, 1996

56 Thomas J, "Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin-induced diabetic C57Bl/6 mice" 25 : 313-318, 2014

57 Tan Y, "Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo" 60 : 625-633, 2011

58 Boudina S, "Diabetic cardiomyopathy revisited" 115 : 3213-3223, 2007

59 Cai L, "Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications" 14 : 2193-2203, 2007

60 Xu J, "Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection" 3 (3): 1499-1512, 2009

61 Velmurugan GV, "Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes" 100 : 143-150, 2013

62 Abo-Salem OM, "Curcumin ameliorates streptozotocin-induced heart injury in rats" 28 : 263-270, 2014

63 Castro CN, "Curcumin ameliorates autoimmune diabetes. Evidences in accelerated murine models of type 1 diabetes" 177 : 149-160, 2014

64 Zhao WC, "Curcumin ameliorated diabetic neuropathy partially by inhibition of NADPH oxidase mediating oxidative stress in the spinal cord" 560 : 81-85, 2014

65 Bresciani L, "Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats" 24 : 408-415, 2014

66 de Zeeuw D, "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease" 369 : 2492-2503, 2013

67 Pergola PE, "Bardoxolone methyl and kidney function in CKD with type 2 diabetes" 365 : 327-336, 2011

68 Chin M, "Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of type 2 diabetes and obesity" 304 : F1438-F1446, 2013

69 Zhang DD, "Bardoxolone brings Nrf2-based therapies to light" 19 : 517-518, 2013

70 Cai L, "Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy" 48 : 1688-1697, 2006

71 Hamblin M, "Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy" 42 : 884-895, 2007

72 Liu X, "Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice" 54 : 778-784, 2005

73 Hsu WH, "A novel natural Nrf2 activator with PPARgamma-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia" 272 : 842-851, 2013

74 Tan SM, "A derivative of Bardoxolone methyl, dh404, in an inverse dose-dependent manner, lessens diabetes-associated atherosclerosis and improves diabetic kidney disease" 63 : 3091-3103, 2014